With more specialty medicines coming to market, the care coordination and financial management associated with high-value therapies is increasing in complexity. Cell and gene therapies have ushered in a new era of logistics where treatments are patient specific. At the same time, the financial management for these therapies is creating new paradigms for sites of care and biopharma sponsors.
Join leading experts at the forefront of this new supply chain management model to further understand:
Shantese Marchbanks, Director, Account Management and New Business Implementation, Cardinal Health 3PL Services
Shantese collaborates with biopharma sponsors to set up new partnerships and programs tailored to their unique market and product needs. By bringing together diverse Cardinal Health 3PL Services departmental leads, Shantese leads the development of consistent methodologies based on best practices. She leverages her certification as a Lean Six Sigma Kaizen leader to identify improvements in business practices and close gaps in operating processes. Shantese has more than 10 years’ experience within Cardinal Health 3PL Services, starting in Accounts Receivables and increasing her scope of responsibility and leadership to encompass the Implementation and Account Management teams. With a background in quality, compliance and finance, Shantese understands the challenges of working in a highly regulated environment, and the high stakes of new product launches in emerging therapeutic categories like precision medicine.
Jon McWhinney, Director, Cardinal Health 3PL Services
As Director of Business Development for Third-Party Logistics Services (3PL) Jon supports pharmaceutical, biotech and drug-device manufacturers in developing optimal commercial solutions to bring their products to market. He applies his analytical and technical background to fluently collaborate with cross-functional stakeholders to build novel solutions. Jon joined Cardinal Health in 2006. This tenure makes him an expert in helping partners navigate the comprehensive capabilities that the organization can offer, from patient support services, regulatory expertise, packaging solutions to global trade advice and support. With a consultative approach, Jon translates customer needs into partnership agreements that support commercialization strategies and timelines. During his time with 3PL Services, Jon has made pivotal contributions to new solutions including physician sample services, title model and order-to-cash services for cell and gene therapies.
Heidi Hagen, Co-Founder, Vineti
Heidi, Co-Founder and Advisor at Vineti, has been an operations executive in the biotechnology industry for over 25 years. She has overseen the delivery of more than 100,000 doses of personalized cell therapy, and has guided numerous therapies through clinical development on to commercialization. She has an extensive and proven track record in leading operations and commercializing innovative technologies ranging from recombinant protein/device combinations to the first active immune cell therapy, Provenge. Heidi is on the Board of Directors for Vericel Inc, Ziopharm Inc and Lykan Biosciences. Previously, Heidi was the Global COO for SOTIO in Prague, Czech Republic, with a U.S. office in Boston, Mass. Before joining SOTIO, she worked for Dendreon for 10 years as Senior Vice President of Operations, and 10 years with Immunex Corporation in a range of roles in drug development and operations management. Heidi has a BS in Cell and Molecular Biology, an MS in Bioengineering and an MBA from the University of Washington.